Opus Genetics COO Schachle reports $16,994 stock sale for taxes

Joseph K. Schachle, Chief Operating Officer of Opus Genetics, Inc. (NASDAQ:IRD), reported the sale of company common stock totaling $16,994 on October 23, 2026. The transaction involved 4,767 shares.

The shares were sold at a price of $3.565 per share. According to a footnote in the filing, the sale was executed automatically on behalf of Mr. Schachle to satisfy tax withholding obligations that arose in connection with the vesting and settlement of restricted stock units. This transaction did not represent a discretionary trade by the reporting person.The sale comes as Opus Genetics shares have declined 17% over the past week, though the stock remains up 65% year-to-date with a current market cap of $286 million.

Following this transaction, Mr. Schachle directly beneficially owns 286,673 shares of Opus Genetics common stock.According to InvestingPro analysis, the stock currently trades near its Fair Value estimate, placing it on the Most Overvalued watchlist. The platform offers 11 additional ProTips for IRD investors seeking deeper insights into the company’s financial health and market position.

In other recent news, Opus Genetics has seen several updates from analysts and developments in its clinical programs. Citizens has maintained a Market Outperform rating with a $17.00 price target, citing potential milestone payments from the approval of Ryzumvi, which could add to Opus Genetics’ cash reserves. Additionally, Citizens noted progress in the company’s BEST1 program, with 75% of evaluable patients in Cohort 1 meeting the pivotal endpoint, which is being applied to Cohort 2. Wedbush has raised its price target for Opus Genetics from $10 to $13, reflecting increased confidence in the company’s alignment with the FDA on pivotal study endpoints for the OPGx-BEST1 program. H.C. Wainwright has reaffirmed a Buy rating and an $8.00 price target ahead of Opus Genetics’ presentation of Phase 1/2 BIRD-1 study topline data. The company is expected to disclose this data during an upcoming investor conference call. Citizens also highlighted the potential for non-dilutive capital from a partnership with Viatris, with a possible $10 million milestone payment anticipated in connection with the Ryzumvi PDUFA date for presbyopia. These developments suggest ongoing progress and potential financial inflows for Opus Genetics.